Miragen Therapeutics (NASDAQ: MGEN) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its peers? We will compare Miragen Therapeutics to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.
Institutional and Insider Ownership
19.0% of Miragen Therapeutics shares are owned by institutional investors. Comparatively, 53.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 44.4% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 16.8% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Miragen Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Miragen Therapeutics Competitors||-110.24%||-188.04%||-38.52%|
This is a summary of current recommendations and price targets for Miragen Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Miragen Therapeutics Competitors||107||449||528||17||2.41|
Miragen Therapeutics presently has a consensus target price of $17.19, suggesting a potential upside of 164.42%. As a group, “Medical laboratories” companies have a potential upside of 17.44%. Given Miragen Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Miragen Therapeutics is more favorable than its peers.
Valuation and Earnings
This table compares Miragen Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Miragen Therapeutics||$4.00 million||-$26.51 million||-4.71|
|Miragen Therapeutics Competitors||$1.13 billion||$77.59 million||202.61|
Miragen Therapeutics’ peers have higher revenue and earnings than Miragen Therapeutics. Miragen Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Miragen Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Miragen Therapeutics’ peers have a beta of 1.24, suggesting that their average stock price is 24% more volatile than the S&P 500.
Miragen Therapeutics peers beat Miragen Therapeutics on 7 of the 13 factors compared.
Miragen Therapeutics Company Profile
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.